A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m
The combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be funded by the NHS in England and Wales after a recommendation from cost regulat
Sanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema drug Dupixent (dupilumab) so it can be used to treat adolescents.
